证券代码：300149 证券简称：睿智医药 公告编号：2026-01 睿智医药科技股份有限公司 关于持股 5%以上股东减持股份的预披露公告 持股5%以上股东梁玉凤、于显文保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、持有睿智医药科技股份有限公司（以下简称"公司"）股份 26,185,660 股（占公司总股本比例 5.26%）的持股 5%以上股东梁玉凤女士计划在本公告披露 之日起十五个交易日后的三个月内以集中竞价或大宗交易方式减持公司股份不超 过 14,938,919 股（占公司总股本比例 3%）。 2、持有公司股份 25,000,000 股（占公司总股本比例 5.02%）的持股 5%以上 股东于显文先生计划在本公告披露之日起十五个交易日后的三个月内以集中竞价 或大宗交易方式减持公司股份不超过 14,938,919 股（占公司总股本比例 3%）。 公司于近日收到持股 5%以上股东梁玉凤女士、于显文先生分别出具的《关 于股份减持计划告知函》，现将相关情况公告如下： | 股东名称 | 持股数量（ ...

Group 1 - The core viewpoint of the articles highlights Ruizhi Pharmaceutical's active advancements in the field of small nucleic acid drug research and production, driven by technological innovation and strategic partnerships to enhance its full-chain service capabilities from laboratory to industrialization [1][2] Group 2 - Ruizhi Pharmaceutical, in collaboration with East China Normal University, launched a drug manufacturing system suitable for ADC and nucleotide monomer synthesis, significantly reducing ADC drug process development time by 70% and lowering nucleotide monomer synthesis costs by over 40% [1] - The company has developed hundreds of modified nucleotides, phosphoramidite monomers, and new linkers, leveraging its capabilities in chemical synthesis and early-stage process development [1] - The company is focusing on delivery system efficiency, which is crucial for the successful commercialization of small nucleic acid drugs, by adopting a phased strategy in collaboration with partners like Haiyou Biotechnology [1] - Ruizhi Pharmaceutical is innovatively integrating Corporate Venture Capital (CVC) and AI-driven scientific research (AI4S) into its strategic layout to enhance project selection and build a technological ecosystem [2] - The chairman of Ruizhi Pharmaceutical emphasized that the computational medicine platform of Zheyuan Technology complements CRO services, aiming to unlock the full potential of the industry by identifying effective research directions [2] - The company aims to build differentiated competitive advantages in small nucleic acid drug research through cost reduction and efficiency improvements, breakthroughs in delivery technology, and expanded applications via full-cycle collaborations [2]

Core Insights - Ruizhi Pharmaceutical Technology Co., Ltd. has developed two automated integrated micro-flow synthesis systems based on its "Super Limit Intelligent Manufacturing" platform, which are currently applied internally to enhance R&D in ADC and small nucleic acid drug fields [1][2] Group 1: Technology and Innovation - The internal application of the Super Limit Intelligent Manufacturing platform focuses on two main areas: enhancing the coupling process for antibody-drug conjugates (ADCs) and synthesizing nucleoside monomers for oligonucleotide drugs, significantly improving development efficiency and overall yield [1] - The ADC drug process development time can be reduced by 70%, while the cost of synthesizing nucleoside monomers can be lowered by over 40% [2] Group 2: Strategic Partnerships and Market Positioning - The drug manufacturing system was jointly released by Ruizhi Pharmaceutical and East China Normal University, emphasizing the establishment of a joint laboratory to improve the transition from laboratory R&D to industrial production [2] - The company is positioning its business around "new modalities (including small nucleic acids)" and "ecological investment," aiming to create more opportunities in the small nucleic acid sector through strategic partnerships with multiple companies [2]

Market Overview - The A-share market experienced a narrow fluctuation with the Shanghai Composite Index down 0.03% at 4163.84 points, the Shenzhen Component down 0.31% at 14321.8 points, and the ChiNext Index down 0.83% at 3360.23 points, as well as the STAR Market Index down 1.77% at 1485.01 points, with a total trading volume of 2.44 trillion yuan and over 2800 stocks declining [1] Hot Sectors - The AI application sector led the market, with stocks like Easy Point World, Liou Shares, and Gravity Media hitting the daily limit, while AI medical concepts remained active with companies like Meian Health and Dean Diagnostics achieving three consecutive limit-ups [2][1] - The innovative drug sector saw significant gains, with Hongbo Pharmaceutical hitting the daily limit and other companies like Chengdu Xian Dao and Rui Zhi Pharmaceutical rising over 10% [3] - The insurance sector remained active, with China Life rising over 4% and other major insurers following suit, driven by policy support and macroeconomic changes [4] Securities Sector - The securities sector showed a rising trend, with Huayin Securities hitting the limit and other firms like Founder Securities and GF Securities also experiencing gains [5] Trading Volume - The trading volume in the Shanghai and Shenzhen markets reached a record high of 3.6 trillion yuan, indicating strong market activity [6] Institutional Insights - Zhongtai Securities noted that the market may maintain active trading under policy support, with long-term funds providing a necessary liquidity condition [7] - Dongfang Securities commented on the current healthy market trend, despite concerns about potential adjustments due to increased trading volume [8][9] - CITIC Securities highlighted the potential impact of the cancellation of export tax rebates for the photovoltaic industry, suggesting short-term challenges but long-term opportunities for high-quality development [10]

Group 1 - The innovative drug concept stocks opened strong, with Hongbo Pharmaceutical hitting the daily limit up of 20% [1] - Chengdu Xian Dao and Ruizhi Pharmaceutical both rose over 10% [1] - Yaoshi Technology, Boji Pharmaceutical, Meidixi, and Haoyuan Pharmaceutical all increased by more than 5% [1]

Group 1 - The core viewpoint of the article highlights the strong performance of AI healthcare and pharmaceutical concepts in the early trading session, with specific companies like Dean Diagnostics and Meien Health achieving consecutive gains [1] - Companies such as Ruizhi Medicine, Innotech, Hongbo Medicine, and Weining Health also experienced upward movement in their stock prices, indicating a broader trend in the sector [1]

证券日报网讯1月7日，睿智医药（300149）在互动平台回答投资者提问时表示，截至2025年12月31日， 公司股东人数为37377户。 ...

Group 1 - The core viewpoint of the news is that Ruizhi Pharmaceutical has shown a positive stock performance with a 2.09% increase on January 7, reaching a price of 10.25 yuan per share, and a total market capitalization of 5.104 billion yuan [1] - As of January 7, 2023, the company has seen a year-to-date stock price increase of 7.22%, with a 6.55% rise over the last five trading days and a 2.60% increase over the last 20 days, while experiencing a 9.29% decline over the last 60 days [1] - The company primarily engages in pharmaceutical research and production outsourcing services, with 99.06% of its revenue coming from these services, while other revenue sources include prebiotic products (0.52%), rental income (0.35%), and other income (0.07%) [1] Group 2 - As of December 20, 2025, Ruizhi Pharmaceutical reported a total revenue of 817 million yuan for the period from January to September, reflecting a year-on-year growth of 13.68%, and a net profit attributable to shareholders of 7.0913 million yuan, which is a significant increase of 111.50% year-on-year [2] - The company has distributed a total of 180 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 24.3258 million shares, a decrease of 6,100 shares compared to the previous period [3]

Market Overview - The Shanghai Composite Index closed at 3968.84 points, with a slight increase of 0.09% [1] - The total trading volume of A-shares reached 2461.743 billion yuan [1] Technical Analysis - A total of 167 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Sanfu New Science (三孚新科) with a difference of -1.68% [1] - Tianjian Technology (天箭科技) with a difference of -1.66% [1] - Zhongmin Energy (中闽能源) with a difference of -1.30% [1] Individual Stock Performance - Sanfu New Science (688359) decreased by 0.25% with a trading turnover of 1.57% [1] - Tianjian Technology (002977) saw a significant drop of 9.99% with a trading turnover of 2.27% [1] - Zhongmin Energy (600163) declined by 2.17% with a trading turnover of 1.33% [1] - Other notable stocks include: - Hainan Ruize (002596) increased by 0.94% [1] - Weidao Nano (688147) decreased by 1.54% [1] - Eighty Billion (688181) increased by 0.31% [1] Additional Stock Movements - Stocks such as Xiling Information (300588) and Zhaolong Interconnect (300913) also showed minor declines of 0.11% and 1.55% respectively [1] - The performance of ST stocks included: - ST Huaxi (002630) with a decrease of 0.40% [1] - ST Meicheng (300237) with a decline of 1.90% [1]

Group 1 - The core viewpoint of the news is that Ruizhi Pharmaceutical has shown a decline in stock performance and financing activities, indicating a low level of investor confidence and market activity [1][2]. - As of December 29, 2023, Ruizhi Pharmaceutical's stock price fell by 0.62%, with a trading volume of 54.76 million yuan. The net financing amount was -3.51 million yuan, indicating more repayments than new purchases [1]. - The total financing and margin trading balance for Ruizhi Pharmaceutical is 154 million yuan, which accounts for 3.22% of its market capitalization, indicating a low financing level compared to the past year [1]. Group 2 - As of December 20, 2023, the number of shareholders for Ruizhi Pharmaceutical decreased by 1.92% to 38,600, while the average number of circulating shares per person increased by 1.96% to 12,307 shares [2]. - For the period from January to September 2025, Ruizhi Pharmaceutical reported a revenue of 817 million yuan, representing a year-on-year growth of 13.68%. The net profit attributable to shareholders was 7.09 million yuan, showing a significant increase of 111.50% year-on-year [2]. - The company has cumulatively distributed 180 million yuan in dividends since its A-share listing, but there have been no dividend distributions in the past three years [3].